Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors. - Wikidata - awgldk - TriplyDB

Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.

Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.

http://www.wikidata.org/entity/Q36913828

about

Neural Stem Cell Carriers for the Treatment of Glioblastoma Multiforme Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging.Neural stem cell therapy for cancer.Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively.Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells.Molecular mechanism matters: Benefits of mechanistic computational models for drug development.Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer.Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin TRAIL on trial: preclinical advances in cancer therapy Shining light on cell death processes - a novel biosensor for necroptosis, a newly described cell death program.Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL.Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme Pro-apoptotic effect of TRAIL-transfected endothelial progenitor cells on glioma cells.

P2860

Q26783167-72AAFD24-CB32-4402-8542-83350C775DB1 Q30544925-2215CEE0-88FC-4B35-B168-9A0359A12544 Q33704489-485D50BD-4981-4597-8A14-AE7735E370A8 Q33709701-49EC3828-C211-4ED4-9671-990115351588 Q34474267-469FD54D-2AD2-4342-BDB1-C698B605165D Q34728592-35916C23-990E-423C-B430-2EA74E176686 Q35974503-BBFCE768-43C8-4A65-815D-F8D59D004044 Q36052870-D667077D-569A-468B-B139-C669E45AEE29 Q36132383-4F166CB9-BFE4-4A06-BE6C-2158DD187E52 Q36684365-8EFC202B-3C4F-4518-9D5F-E44239476BF5 Q37061007-5693C373-27B7-4DAF-A3DD-26FE3F42A835 Q37433463-6FBDF088-812E-4B98-AFCE-1150E9FA84D6 Q38175903-EE9D9266-686D-41C4-B12D-66852DEAFB68 Q38960128-04D01398-011E-48AB-A441-024129725FF5 Q41084396-8BF96262-93E7-4201-A32B-767E69B17EF5 Q42577813-47BAD69C-F7DB-4854-A189-1048B4D40E06 Q52653034-30A5F029-0F17-4019-AB35-B0C02871D78A

P2860

Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.

http://www.wikidata.org/entity/Q36913828

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Real-time imaging of the dynam ...... me TRAIL resistance in tumors.

@en

type

label

Real-time imaging of the dynam ...... me TRAIL resistance in tumors.

@en

prefLabel

Real-time imaging of the dynam ...... me TRAIL resistance in tumors.

@en

P1433

Q36913828-B8E4D4CB-9FB9-4FF3-B9A3-58B60305056A

P1476

Q36913828-FE7A5692-B1D8-4050-9A9B-15AB8D0182F0

P2093

Q36913828-13911A58-92F6-4213-8F4B-BF3607138946

Q36913828-15BE2ADF-4364-49D6-8DA2-0D6D137D2CF9

Q36913828-4252DE39-4F24-4C31-A209-E1EE60C96B4B

Q36913828-471A9A95-B8CB-4DDE-8C08-DA14827E5814

Q36913828-725845C2-1C6C-4259-984D-C9E314F3F312

Q36913828-8C2363AB-1525-4525-AE3E-0333485661D5

P2860

Q36913828-089CF547-EE92-479C-AC9D-0CD35C50BE1F

Q36913828-0B84628E-67C4-4247-8452-4C62C86D071F

Q36913828-108E64D4-9CE3-4094-A1FB-71917A5A42B8

Q36913828-142BCA13-AE79-494F-B163-C9C9C93947E1

Q36913828-1578A135-66AF-474F-BD97-3803D8CFD47F

Q36913828-3B2F77CC-BC30-464F-B3A1-83B842689535

Q36913828-3BAF364B-0466-468D-A755-31C2404503CD

Q36913828-40472E81-7827-456A-9990-F9019E4C97E7

Q36913828-4265DD18-6842-4900-AA5E-EC85F0827057

Q36913828-436AD6BC-949A-4A8C-9382-4F637222DF64

P2888

Q36913828-1F9B8E1A-FCE7-4562-B52D-F0D0529264CF

P304

Q36913828-AD83E8E0-DF2B-4D7A-90E4-AD3E9BCF3B6A

P31

Q36913828-C4D778E9-5301-4BAA-B3E2-33509411D5F7

P356

Q36913828-6F89A42F-B83F-459D-8D2C-4E022DC8B3F0

P407

Q36913828-53B99D7D-3CA2-455C-B445-212D5388BBC2

P433

Q36913828-77B670E9-A2DC-421E-8F12-37869AF432C3

P478

Q36913828-4DD7D1AA-2951-4246-BE49-C52DF00E1558

P577

Q36913828-1A760451-F25D-4439-9B7B-13B0EFB1F292

P5875

Q36913828-8A209674-FBE5-483A-BA40-A8A3A1A2FD3B

P6179

Q36913828-2A1B73EC-A158-475F-85AC-E0212667BC54

P698

Q36913828-71634A44-9208-4506-87B0-6A6B9BDD9761

P932

Q36913828-6DFD8A53-25AD-4ED6-B900-28A4F07F8E97

P356

P1433

P1476

Real-time imaging of the dynam ...... me TRAIL resistance in tumors.

@en

P2093

A Agarwal

http://www.w3.org/2001/XMLSchema#string

D Flusberg

http://www.w3.org/2001/XMLSchema#string

K Shah

http://www.w3.org/2001/XMLSchema#string

P Sorger

http://www.w3.org/2001/XMLSchema#string

S Wanningen

http://www.w3.org/2001/XMLSchema#string

T Bagci-Onder

http://www.w3.org/2001/XMLSchema#string

P2860

Modeling a snap-action, variable-delay switch controlling extrinsic cell death

Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis.

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells

Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins.

Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors.

Quantitative analysis of pathways controlling extrinsic apoptosis in single cells

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.

Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.

A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.

Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL.

P2888

P304

2818-2827

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2012.304

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229552737

http://www.w3.org/2001/XMLSchema#string

P6179

1013622871

http://www.w3.org/2001/XMLSchema#string

P698

22824792

http://www.w3.org/2001/XMLSchema#string

P932

3676868

http://www.w3.org/2001/XMLSchema#string